{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T12:40:41Z","timestamp":1791636041929,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022023","name":"Brandenburgische Technische Universit\u00e4t Cottbus - Senftenberg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100022023","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We aimed to generate a HepG2 cell clone stably overexpressing cytochrome P450 (CYP) 2C9 together with an empty vector (EV) control cell clone for pharmacological and toxicological studies of substances with CYP2C9-mediated biotransformation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A new HepG2 cell clone was generated by lentiviral transduction to functionally overexpress human CYP2C9. We found high CYP2C9 transcript and protein levels based on qRT-PCR, Western blot and immunofluorescence in the cell clone. Most importantly, specific enzyme activities of 62.9\u2009\u00b1\u20092.6 pmol 4-hydroxydiclofenac\/min\/10\n                      <jats:sup>6<\/jats:sup>\n                      cells as analyzed by diclofenac conversion via liquid chromatography-mass spectrometry were found in HepG2-CYP2C9 cells. CYP2C9 enzyme activity could successfully be inhibited by the application of the pan-CYP inhibitor 1-aminobenzotriazole or the CYP2C9-specific inhibitor sulfaphenazole. No changes in morphology or population doubling times were detected when comparing the clone to parental HepG2 cells. The corresponding EV control cell line was detected negative for CYP2C9 expression in all experimental setups and did not show any difference to the parental HepG2 cells. Thus, the newly established HepG2-CYP2C9 cell line is an appropriate tool to study metabolism and toxicity of substances depending on conversion by CYP2C9.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-026-07935-y","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:25:59Z","timestamp":1782851159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phenotypical and functional characterization of a HepG2 cell clone stably overexpressing cytochrome P450 (CYP) 2C9"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9284-2242","authenticated-orcid":false,"given":"Sarah","family":"Kammerer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"Jenchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika","family":"Ruzsanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Heiner","family":"K\u00fcpper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"2","key":"7935_CR1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00204-020-02937-6","volume":"95","author":"R Gupta","year":"2021","unstructured":"Gupta R, Schrooders Y, Hauser D, van Herwijnen M, Albrecht W, Ter Braak B, et al. Comparing in vitro human liver models to in vivo human liver using RNA-Seq. Arch Toxicol. 2021;95(2):573\u201389.","journal-title":"Arch Toxicol"},{"issue":"10","key":"7935_CR2","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","volume":"40","author":"D Lopez-Terrada","year":"2009","unstructured":"Lopez-Terrada D, Cheung SW, Finegold MJ, Knowles BB. Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol. 2009;40(10):1512\u20135.","journal-title":"Hum Pathol"},{"issue":"8","key":"7935_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1124\/dmd.31.8.1035","volume":"31","author":"S Wilkening","year":"2003","unstructured":"Wilkening S, Stahl F, Bader A. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 2003;31(8):1035\u201342.","journal-title":"Drug Metab Dispos"},{"key":"7935_CR4","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cbi.2015.10.009","volume":"255","author":"J Xuan","year":"2016","unstructured":"Xuan J, Chen S, Ning B, Tolleson WH, Guo L. Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity. Chem Biol Interact. 2016;255:63\u201373.","journal-title":"Chem Biol Interact"},{"key":"7935_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.tox.2018.11.008","volume":"412","author":"S Steinbrecht","year":"2019","unstructured":"Steinbrecht S, Konig R, Schmidtke KU, Herzog N, Scheibner K, Kruger-Genge A, et al. Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4. Toxicology. 2019;412:37\u201347.","journal-title":"Toxicology"},{"issue":"11","key":"7935_CR6","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1080\/10408398.2022.2131728","volume":"64","author":"X Sun","year":"2024","unstructured":"Sun X, Ye Y, Sun J, Tang L, Yang X, Sun X. Advances in the study of liver microsomes in the in vitro metabolism and toxicity evaluation of foodborne contaminants. Crit Rev Food Sci Nutr. 2024;64(11):3264\u201378.","journal-title":"Crit Rev Food Sci Nutr"},{"key":"7935_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm8010001","volume":"8","author":"AK Daly","year":"2017","unstructured":"Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: functional and clinical considerations. J Pers Med. 2017;8:1.","journal-title":"J Pers Med"},{"issue":"27","key":"7935_CR8","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.2174\/092986709789057635","volume":"16","author":"SF Zhou","year":"2009","unstructured":"Zhou SF, Zhou ZW, Yang LP, Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480\u2013675.","journal-title":"Curr Med Chem"},{"issue":"18","key":"7935_CR9","doi-asserted-by":"publisher","first-page":"e202500492","DOI":"10.1002\/cmdc.202500492","volume":"20","author":"V Stock","year":"2025","unstructured":"Stock V, Hofer R, Liedl KR, Troppmair J, Langer T, Gstach H, et al. Towards the use of metabolic volatiles in breath for determining drug response: gstachamine as an unlabeled substrate to measure CYP3A4 activity. ChemMedChem. 2025;20(18):e202500492.","journal-title":"ChemMedChem"},{"issue":"1","key":"7935_CR10","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/s41598-025-86450-9","volume":"15","author":"V Stock","year":"2025","unstructured":"Stock V, Hofer R, Lochmann F, Spanke V, Liedl KR, Troppmair J, et al. Tolterodine is a novel candidate for assessing CYP3A4 activity through metabolic volatiles to predict drug responses. Sci Rep. 2025;15(1):2462.","journal-title":"Sci Rep"},{"key":"7935_CR11","doi-asserted-by":"publisher","first-page":"108772","DOI":"10.1016\/j.bioorg.2025.108772","volume":"163","author":"V Stock","year":"2025","unstructured":"Stock V, Hofer R, Spanke VA, Liedl KR, Troppmair J, Langer T, et al. Diisopromine as a non-labelled CYP3A4 substrate: Implications for breath test development. Bioorg Chem. 2025;163:108772.","journal-title":"Bioorg Chem"},{"issue":"1","key":"7935_CR12","first-page":"68","volume":"39","author":"S Chen","year":"2021","unstructured":"Chen S, Wu Q, Li X, Li D, Mei N, Ning B, et al. Characterization of cytochrome P450s (CYP)-overexpressing HepG2 cells for assessing drug and chemical-induced liver toxicity. J Environ Sci Health C. 2021;39(1):68\u201386.","journal-title":"J Environ Sci Health C"},{"issue":"3","key":"7935_CR13","first-page":"038","volume":"8","author":"PRO de Montellano","year":"2018","unstructured":"de Montellano PRO. 1-Aminobenzotriazole: a mechanism-based cytochrome P450 inhibitor and probe of cytochrome P450 biology. Med Chem (Los Angel). 2018;8(3):038.","journal-title":"Med Chem (Los Angel)"},{"issue":"2","key":"7935_CR14","doi-asserted-by":"publisher","first-page":"621","DOI":"10.3390\/molecules28020621","volume":"28","author":"MC van Bouwmeester","year":"2023","unstructured":"Bouwmeester MC, Tao Y, Proen\u00e7a S, van Steenbeek FG, Samsom RA, Nijmeijer SM, et al. Drug metabolism of hepatocyte-like organoids and their applicability in in vitro toxicity testing. Molecules. 2023;28(2):621.","journal-title":"Molecules"},{"issue":"5","key":"7935_CR15","doi-asserted-by":"publisher","first-page":"e10947","DOI":"10.15252\/msb.202210947","volume":"18","author":"L Niu","year":"2022","unstructured":"Niu L, Geyer PE, Gupta R, Santos A, Meier F, Doll S, et al. Dynamic human liver proteome atlas reveals functional insights into disease pathways. Mol Syst Biol. 2022;18(5):e10947.","journal-title":"Mol Syst Biol"},{"issue":"5","key":"7935_CR16","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.bcp.2013.06.029","volume":"86","author":"M Ulvestad","year":"2013","unstructured":"Ulvestad M, Nordell P, Asplund A, Rehnstrom M, Jacobsson S, Holmgren G, et al. Drug metabolizing enzyme and transporter protein profiles of hepatocytes derived from human embryonic and induced pluripotent stem cells. Biochem Pharmacol. 2013;86(5):691\u2013702.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"7935_CR17","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1517\/17425255.4.7.837","volume":"4","author":"MJ Gomez-Lechon","year":"2008","unstructured":"Gomez-Lechon MJ, Castell JV, Donato MT. An update on metabolism studies using human hepatocytes in primary culture. Expert Opin Drug Metab Toxicol. 2008;4(7):837\u201354.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"50","key":"7935_CR18","doi-asserted-by":"publisher","first-page":"16205","DOI":"10.1021\/bi961950t","volume":"35","author":"A Mancy","year":"1996","unstructured":"Mancy A, Dijols S, Poli S, Guengerich P, Mansuy D. Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2\u00a0C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9. Biochemistry. 1996;35(50):16205\u201312.","journal-title":"Biochemistry"},{"issue":"5","key":"7935_CR19","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/S0006-2952(99)00167-7","volume":"58","author":"R Bort","year":"1999","unstructured":"Bort R, Mac\u00e9 K, Boobis A, G\u00f3mez-Lech\u00f3n MJ, Pfeifer A, Castell J. Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem Pharmacol. 1999;58(5):787\u201396.","journal-title":"Biochem Pharmacol"},{"issue":"43","key":"7935_CR20","doi-asserted-by":"publisher","first-page":"14264","DOI":"10.1021\/bi991195u","volume":"38","author":"A Mancy","year":"1999","unstructured":"Mancy A, Antignac M, Minoletti C, Dijols S, Mouries V, Ha Duong N-T, et al. Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999;38(43):14264\u201370.","journal-title":"Biochemistry"},{"key":"7935_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fphar.2016.00443","volume":"7","author":"B Berger","year":"2016","unstructured":"Berger B, Donzelli M, Maseneni S, Boess F, Roth A, Krahenbuhl S, et al. Comparison of liver cell models using the basel phenotyping cocktail. Front Pharmacol. 2016;7:443.","journal-title":"Front Pharmacol"},{"issue":"1","key":"7935_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/JCB-189013","volume":"5","author":"S Steinbrecht","year":"2019","unstructured":"Steinbrecht S, Kammerer S, K\u00fcpper JH. HepG2 cells with recombinant cytochrome P450 enzyme overexpression: their use and limitation as in vitro liver model. J Cell Biotechnol. 2019;5(1):55\u201364.","journal-title":"J Cell Biotechnol"},{"issue":"2","key":"7935_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3233\/JCB-179012","volume":"3","author":"S Kammerer","year":"2018","unstructured":"Kammerer S, K\u00fcpper J-H. Human hepatocyte systems for in vitro toxicology analysis. J Cell Biotechnol. 2018;3(2):85\u201393.","journal-title":"J Cell Biotechnol"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-026-07935-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07935-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-026-07935-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:46:55Z","timestamp":1782852415000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13104-026-07935-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7935"],"URL":"https:\/\/doi.org\/10.1186\/s13104-026-07935-y","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"264"}}